Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011)
TSX Venture: QPT
EDMONTON, Nov. 1, 2011 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it will be making a presentation at the 2nd Biennial Meeting of the Asian Society of Gynecologic Oncology, in Seoul, South Korea, November 3-5. The presentation, entitled "Targeting Dendritic Cells to Create a More Powerful Immune Response: A New Approach for the Immunotherapy of Ovarian Cancer using anti-CA125 MAb, Oregovomab", will be presented by Dr. Chris Nicodemus, Chief Scientific Officer of Advanced Immune Therapeutics and Chairman of Quest's Clinical Advisory Board. Dr. Jonathan S. Berek, Professor and Director, Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, and Chair, Cooperative Ovarian Cancer Group, Stanford, California , is one of the co-authors of this presentation, along with Dr. Madi R. Madiyalakan, CEO of Quest. Dr. Berek has also been invited to make a presentation on 'Genetics of Ovarian Cancer' during the conference.
The Company's presentation will highlight its clinical experience with the immunotherapy of ovarian cancer using oregovomab, its unique mechanism in targeting dendritic cells to activate cytotoxic T cell responses, and the Company's strategy of using combinatorial therapies (chemotherapy and/or immuno-adjuvants) to better mobilize anti-tumor immunity. Dendritic cell based immunotherapeutic strategies are gaining momentum in recent days, especially after the award of this year's Noble Prize in Medicine for the discovery of the central role of dendritic cells in mobilizing the adaptive immune system.
"With a large shareholder base in South Korea, this is an excellent opportunity for Quest to present to the Asian gynecologic oncology community our unique approach for immunotherapy of ovarian cancer", said Dr. Madiyalakan, who will also be attending the ASGO conference.
The Company is in the process of translating its valuable intellectual property into commercial success by conducting three carefully planned proof-of-concept clinical trials to establish the superiority of combinatorial immunotherapy either with front-line chemotherapy consisting of carboplatin/paclitaxel in ovarian cancer, gemcitabine in pancreatic cancer, or with the addition of an immunoadjuvant. The Company hopes that successful results from these studies will lead to the design of a definitive product registration study.
About Quest PharmaTech Inc.
Quest is a publicly traded, Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy or photodynamic therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.